Generating real‐world evidence on diabetes technology using the CareLink Personal data management system
Open Access
- 4 September 2024
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (11) , 4846-4853
Abstract
Aim: To establish trust in real‐world evidence (RWE) derived from CareLink Personal (CP), Medtronic's data management system for MiniMed system users, we show that this database and its analyses strictly adhere to the principles of RWE. Methods: The methodology is applicable to all MiniMed iterations. We described every step from raw data to predefined outcomes. In addition, we showed CP's fitness‐for‐research by the below metrics (using last year's MiniMed 780G system data as a case study): representative population, relevant endpoints, appropriate granularity, high data completeness, high data representativity and consistency in results. Results: The process from raw data to outcomes has been validated, and metrics/logics adhere to established definitions. Over 95% of users have a CP account; with 96% providing consent, this allows the use of >91% of the census population. There is no rationale for an over‐representation of a specific phenotype among users not included. CP includes >50 endpoints, including ‘International Consensus on Time in Range’ based metrics. Data are recorded at 5‐min intervals (maximum 288 per day), and on average there were 263 data points per person per day. Ninety‐nine per cent of uploads were automated. For the last year, only 1 in 6 users had a data gap >1 day, and 1 in 50 had a gap >1 week. The time in range from in‐silico studies was similar to that of real‐world studies from different geographies and with ever growing populations. Conclusion: RWE from CP adheres to the principles of RWE and can serve as robust evidence on the performance and safety of MiniMed systems.Keywords
This publication has 18 references indexed in Scilit:
- MiniMed 780G System Outperforms Other Automated Insulin Systems Due to Algorithm Design, Not Bias: Response to Inaccurate AllegationsDiabetes Technology & Therapeutics, 2024
- Real-World Evidence of Omnipod ® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 DiabetesDiabetes Technology & Therapeutics, 2024
- Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical EvidenceDiabetes Technology & Therapeutics, 2024
- Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United StatesDiabetes Technology & Therapeutics, 2024
- Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 SensorDiabetes Technology & Therapeutics, 2023
- The challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: expert panel recommendationsCurrent Medical Research and Opinion, 2022
- Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 UsersDiabetes Technology & Therapeutics, 2022
- Real‐World Evidence in EU Medicines Regulation: Enabling Use and Establishing ValueClinical Pharmacology & Therapeutics, 2021
- Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency InitiativeValue in Health, 2020
- Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized StudiesJAMA, 2001